MedTrace Logo

Whole-genome Sequencing Study in Patients With Diminished Ovarian Reserve

NCT04711772 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 140

Last updated 2021-01-15

No results posted yet for this study

Summary

The study aims to explore the genetic pathogenesis of diminished ovarian reserve via whole-genome sequencing technology in Chinese women.

Conditions

  • Diminished Ovarian Reserve

Interventions

OTHER

whole-genome sequencing

Whole-genome sequencing will be preformed for each participate to explore the potential disease-causing genes of DOR.

Sponsors & Collaborators

  • Ferring Pharmaceuticals

    collaborator INDUSTRY

  • Nanfang Hospital, Southern Medical University

    lead OTHER

Principal Investigators

  • Shi-ling Chen, M.D, Ph.D · Nanfang Hospital, Southern Medical University

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-01
Primary Completion
2022-06-30
Completion
2022-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04711772 on ClinicalTrials.gov